Clinical trials for Multiple myeloma
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center · PI: Richard T Lee
- RECRUITINGPhase 3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda · PI: Study Director
- RECRUITINGPhase 4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval · PI: Dr Julie Côté, MD,FRCPC
- RECRUITINGN/ANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine · PI: Jessica Hahne, MA, MPH
- RECRUITINGEarly Phase 1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPhase 1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPhase 3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.
- RECRUITINGN/ANCT07359014Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple MyelomaSecond Affiliated Hospital, School of Medicine, Zhejiang University · PI: Wenbin Qian, Dr.
- RECRUITINGPhase 3NCT07413809Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing RegimenThe Affiliated People's Hospital of Ningbo University · PI: Peipei Ye
- RECRUITINGPhase 2NCT07188090Mozobil for Autologous Hematopoietic Stem Cell TransplantationThomas Jefferson University · PI: Xia Bi, MD, MS
- RECRUITINGPhase 2NCT07106671A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple MyelomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07051850Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional ImmunotherapiesSung-Soo Park
- RECRUITINGEarly Phase 1NCT06663046Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple MyelomaWondercel Biotech (ShenZhen) · PI: Pengcheng He, M.D. Ph.D.
- RECRUITINGPhase 2NCT06461988Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaStanford University · PI: Surbhi Sidana, MD
- RECRUITINGPhase 2NCT06976476Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and HypogammaglobulinemiaMemorial Sloan Kettering Cancer Center · PI: Zainab Shahid, MBBS
- RECRUITINGPHASE2, PHASE3NCT07202078Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)Monash University · PI: Zoe McQuilten, Professor
- RECRUITINGPHASE2, PHASE3NCT07202052Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)Monash University · PI: Zoe McQuilten, Professor
- RECRUITINGPHASE2, PHASE3NCT07202065Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)Monash University · PI: Zoe McQuilten, Professor
- RECRUITINGPhase 1NCT06622005SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRoswell Park Cancer Institute · PI: Jens Hillengass, MD
- RECRUITINGN/ANCT07248176Universal CAR-T Cell Therapy for MMBioray Laboratories · PI: Ping Li, PhD
- RECRUITINGPhase 1NCT06523699Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell TransplantWashington University School of Medicine · PI: Dilan A Patel, M.D.
- RECRUITINGPhase 2NCT06421675Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple MyelomaOntario Clinical Oncology Group (OCOG) · PI: Hira Mian, MD
- RECRUITINGNCT06644625CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot StudyWake Forest University Health Sciences · PI: Manisha Bhutani, MD
- RECRUITINGPhase 2NCT06523621Nivolumab in Multiple Myeloma Patients After Idecabtagene VicleucelWake Forest University Health Sciences · PI: Barry A Paul, MD
- RECRUITINGPhase 1NCT06799026A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple MyelomaDavid Avigan · PI: David Avigan, MD
- RECRUITINGNCT06846905Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.University Hospital, Toulouse
- RECRUITINGPhase 1NCT06465316Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaNational Cancer Institute (NCI) · PI: Ricardo D Parrondo
- RECRUITINGN/ANCT06697483Risk Stratification and MRD-driven Maintenance for MM After ASCTPeking University People's Hospital
- RECRUITINGEarly Phase 1NCT05846880VitD3 Supplementation in Patients With Multiple MyelomaAmany Keruakous, MD, MS. · PI: Amany Keruakous, MD
- RECRUITINGPhase 2NCT06140524A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple MyelomaRegeneron Pharmaceuticals · PI: Clinical Trial Management
- ACTIVE NOT RECRUITINGNCT06452446Telehealth-based Symptom Management for Veterans Treated With SelinexorDurham VA Medical Center · PI: Daphne Friedman, MD
- RECRUITINGPhase 1NCT06185751Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple MyelomaWashington University School of Medicine · PI: Armin Ghobadi, M.D.
- RECRUITINGPhase 2NCT06376526IMMUNOPLANT for Newly Diagnosed Multiple MyelomaDickran Kazandjian, MD · PI: Dickran Kazandjian, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04876248Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell TransplantRoswell Park Cancer Institute · PI: Jens Hillengass
- RECRUITINGPhase 3NCT06520176Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsThe Affiliated People's Hospital of Ningbo University · PI: Ying Lu
- RECRUITINGPhase 2NCT06207799Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaM.D. Anderson Cancer Center · PI: Qaiser Bashir, MD
- RECRUITINGNCT06338150Precision Medicine StudyIcahn School of Medicine at Mount Sinai · PI: Cesar Rodriguez Valdes, MD, PhD
- RECRUITINGPhase 2NCT06430736PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)Insel Gruppe AG, University Hospital Bern · PI: Thomas Pabst, Prof.
- RECRUITINGPhase 2NCT06505369Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma PatientsNorth Estonia Medical Centre · PI: Diana Loigom, MD
- RECRUITINGEarly Phase 1NCT06407947Study of CT071 Injection in High Risk Newly Diagnosed Multiple MyelomaShanghai Changzheng Hospital
- ACTIVE NOT RECRUITINGN/ANCT07088783Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma PatientsOzlem
- RECRUITINGNCT05530096Telo Genomics Technology to Detect & Profile Multiple Myeloma MRDSir Mortimer B. Davis - Jewish General Hospital · PI: Rayan Kaedbey
- RECRUITINGPHASE1, PHASE2NCT06503107Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMMUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPhase 1NCT06042725MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaMayo Clinic · PI: Shaji K. Kumar, MD
- RECRUITINGPhase 1NCT06215118A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)Pfizer · PI: Pfizer CT.gov Call Center
- RECRUITINGPHASE1, PHASE2NCT06235229A Study of GC012F in Patients With Relapsed/Refractory Multiple MyelomaGracell Biotechnologies (Shanghai) Co., Ltd.
- RECRUITINGPhase 2NCT06107738Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple MyelomaBarbara Ann Karmanos Cancer Institute · PI: Jeffrey Zonder, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT05911321Isa-Pom-Dex in Elderly/Frail Subjects With RRMMUNC Lineberger Comprehensive Cancer Center · PI: Eben I Lichtman, MD
- RECRUITINGNCT06463717Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or NotFirst Affiliated Hospital of Zhejiang University · PI: Haitao Meng
- RECRUITINGPHASE1, PHASE2NCT06066359Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple MyelomaM.D. Anderson Cancer Center · PI: Muzaffar Qazilbash, M D
- RECRUITINGPhase 2NCT06189833Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSStichting European Myeloma Network
- RECRUITINGPhase 2NCT06158412All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple MyelomaThe First Affiliated Hospital of Xiamen University · PI: Zhijuan Lin
- ACTIVE NOT RECRUITINGNCT06126341A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell DisordersMemorial Sloan Kettering Cancer Center · PI: Heather Landau, MD
- RECRUITINGPhase 2NCT05972135Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaSCRI Development Innovations, LLC · PI: Peter A. Forsberg, MD
- RECRUITINGNCT05879757Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary ImmunodeficiencyTakeda · PI: Study Director
- RECRUITINGPhase 3NCT05561387Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentSWOG Cancer Research Network · PI: Sikander Ailawadhi
- RECRUITINGNCT06082284A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.Zhujiang Hospital · PI: Hongwei Zhou, Professor
- RECRUITINGPhase 2NCT05597345Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple MyelomaUniversity of Rochester · PI: Jodi Lipof
- RECRUITINGPhase 2NCT05776979Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsM.D. Anderson Cancer Center · PI: Muzzaffar Qazilbash, MD
- ACTIVE NOT RECRUITINGNCT05844033Biomarker for Infection Risk in CLL and MMMassachusetts General Hospital · PI: Jacob Soumerai, MD
- RECRUITINGPHASE1, PHASE2NCT05850234A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple MyelomaAstraZeneca
- RECRUITINGNCT05965115The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE StudyShanghai Zhongshan Hospital · PI: Peng Liu, PhD, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05690984Elimination of Minimal Residual Disease After TransplantMedical College of Wisconsin · PI: Sabarinath Radhakrishnan, MD
- RECRUITINGPhase 3NCT05827016A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaBristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT05908409A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesIDP Discovery Pharma S.L. · PI: Enrique Ocio San Miguel, MD, PhD
- RECRUITINGPhase 2NCT05789303Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaUniversity of Chicago · PI: Benjamin Derman, MD
- ACTIVE NOT RECRUITINGNCT05742217A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related DiseasesPfizer · PI: Pfizer CT.gov Call Center
- ACTIVE NOT RECRUITINGPhase 2NCT05767359CAR- PRISM (PRecision Intervention Smoldering Myeloma)Dana-Farber Cancer Institute · PI: Irene Ghobrial, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05669989International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabSanofi · PI: Clinical Sciences & Operations
- ACTIVE NOT RECRUITINGPhase 1NCT05775094A Study of Romosozumab in Women With Multiple Myeloma and OsteoporosisMemorial Sloan Kettering Cancer Center · PI: Carlyn Tan, MD
- ACTIVE NOT RECRUITINGNCT05673083Impact of a Health Technology Intervention on Patient Activation in Multiple MyelomaAll4Cure
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05434689COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomideUniversity of Alabama at Birmingham · PI: Luciano Costa, MD, PhD
- RECRUITINGPhase 2NCT05344833Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple MyelomaUniversity of Illinois at Chicago
- RECRUITINGNCT07111884GMMG Multiple Myeloma RegistryProf. Dr. Hartmut Goldschmidt · PI: Hartmut Goldschmidt, Prof.
- ACTIVE NOT RECRUITINGPhase 1NCT05556798A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentMemorial Sloan Kettering Cancer Center · PI: Malin Hultcrantz, MD, PhD
- RECRUITINGNCT06659276Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple MyelomaIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGNCT06154902Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene VicleucelBristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGPhase 2NCT05208307Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaEmory University · PI: Ajay K. Nooka, MD,MPH,FACP
- RECRUITINGPhase 2NCT05336383Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple MyelomaM.D. Anderson Cancer Center · PI: Penny Fang, MD
- RECRUITINGPhase 2NCT05393804A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell TransplantMemorial Sloan Kettering Cancer Center · PI: Gunjan Shah, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05354557Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)Memorial Sloan Kettering Cancer Center · PI: Gunjan Shaw, MD
- ACTIVE NOT RECRUITINGNCT05271630Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell TransplantH. Lee Moffitt Cancer Center and Research Institute · PI: Doris Hansen, MD
- ACTIVE NOT RECRUITINGPhase 3NCT05317416Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantPfizer · PI: Pfizer CT.gov Call Center
- ACTIVE NOT RECRUITINGNCT04985643A Study of Real Life Treatment for Multiple Myeloma (MM)Takeda · PI: Study Director
- ACTIVE NOT RECRUITINGPhase 3NCT06956170All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaGlaxoSmithKline
- ACTIVE NOT RECRUITINGPhase 2NCT04835129Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaMedical College of Wisconsin · PI: Binod Dhakal, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05130827Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)Memorial Sloan Kettering Cancer Center · PI: Gunjan Shah, MD, MS
- RECRUITINGPHASE1, PHASE2NCT05060627Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomidePETHEMA Foundation · PI: Paula Rodríguez Otero
- ACTIVE NOT RECRUITINGNCT05013190A Study of NINLARO® in Chinese Adults With Multiple MyelomaTakeda · PI: Study Director
- ACTIVE NOT RECRUITINGPhase 2NCT04302324A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to DaratumumabWeill Medical College of Cornell University · PI: Cara Rosenbaum, MD
- RECRUITINGPHASE1, PHASE2NCT05243212Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple MyelomaSheba Medical Center
- ACTIVE NOT RECRUITINGPhase 2NCT04883242Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaUniversity of Washington · PI: Rahul Banerjee, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04635189Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple MyelomaUniversity of Rochester · PI: Frank Passero, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04751877Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).Poitiers University Hospital · PI: LELEU Xavier, Prof.
- ACTIVE NOT RECRUITINGPhase 3NCT04939142A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)Antengene Corporation · PI: Jin Lu, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT04656951Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First RelapseUniversity of Cologne · PI: Christof Scheid, Prof. Dr.
- RECRUITINGPHASE1, PHASE2NCT04822337Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaWake Forest University Health Sciences · PI: Shebli Atrash, MD, MS
- RECRUITINGN/ANCT04533217Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.Spine Centre of Southern Denmark · PI: Mikkel Andersen, Professor
- RECRUITINGPhase 3NCT04566328Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialECOG-ACRIN Cancer Research Group · PI: Shaji K Kumar
- ACTIVE NOT RECRUITINGPhase 2NCT04564703Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM PatientsStichting European Myeloma Network · PI: Francesca Gay, MD